Metallic hemiarthroplasty for the treatment of end stage hallux rigidus: mid-term implant survival, functional outcome and cost analysis

G. Dall, N. Clement, D. McDonald, I. Ahmed, A. Duckworth, H. Shalaby, J. McKinley

¹NHS Lothian, Orthopaedics, Edinburgh, United Kingdom 

Introduction: We present a review of 97 consecutive BioPro^® metallic hemiarthroplasties performed in 80 patients for end-stage hallux rigidus, with a minimum of five years follow-up.

Results: The mean age of the cohort was 55 (22 to 74) years. No patient was lost to follow-up. There were 15 revisions performed, one for infection, two for osteolysis, and 12 for pain. The all cause survival rate at five years was 85.6% (95% confidence interval (CI) 83.5 to 87.9). Younger age was a significant predictor of revision (odds ratio 1.09, 95% CI 1.02 to 1.17, p=0.014) on excluding infection and adjusting for confounding variables (Cox regression). Significant improvements were demonstrated at 5 years in the Manchester Oxford foot questionnaire (13.9, 95% CI 10.5 to 17.2) and in the physical component of the short form 12 score (6.5, 95% CI 4.1 to 8.9). The overall satisfaction rate was 72%. The cost per quality-adjusted-life-year at 5 years, accounting for a 3% per year revision rate, was £3,714.

Conclusion: The BioPro offers good short to mid-term functional outcome and is a cost effective intervention. The relative high revision rate is associated with younger age and the use of this implant may be limited to older patients.

Click thumbnail below to view poster / thumbnail: